Today’s Advancements In Patient Treatments
Since then, there has been staggering momentum of iPSC and other cell therapy approvals accompanied by potentially life-changing results. In 2021, for example, Vertex Pharmaceuticals successfully treated a type 1 diabetic patient using VX-880—a stem cell-derived pancreatic islet cell replacement therapy. More recently, biotech companies Sernova and Evotec announced that the first two patients in the second cohort of their active diabetes clinical trial have been implanted with off-the-shelf, induced pluripotent stem cell (iPSC)-based islet replacement therapy.
Forbes may have the details wrong, BUT Sernova got press there!